Skip to main content
Clinical Trials/NCT03445624
NCT03445624
Completed
Not Applicable

Abdominal Ultrasound With Doppler and Peripheral Hemogram in Assesment Inflammatory Bowel Disease

Assiut University1 site in 1 country60 target enrollmentJuly 1, 2018

Overview

Phase
Not Applicable
Intervention
Infliximab
Conditions
Inflammatory Bowel Diseases
Sponsor
Assiut University
Enrollment
60
Locations
1
Primary Endpoint
the role abdominal ultrasound in assessment inflammatory bowel disease
Status
Completed
Last Updated
2 years ago

Overview

Brief Summary

assessment of inflammatory bowel disease patients in activity and remission by abdominal ultrasound examine non-invasive and in physiological condition by measuring the colon wall thickness in diagnosis and follow up the patient also including extra intestinal features such as the splanchnic vessels,mesentery and lymph nodes . Doppler u.s can evaluate bowel wall vascularity In activity and remission . peripheral hemogram in relationship to activity inflammatory bowel disease asses anemia ,increase monocyte and decrease mean platelet volume( MPV) . also,the investigator will evaluate the outcome of different lines of treatment traditional and biologic therapy (response to treatment,times of activity and complications)

Detailed Description

the participants will follow up the patient for 1 year in the first visit All patients in this study will be subjected to: 1. Detailed history. 2. Careful physical examination 3. laboratory investigation 1. complete blood picture. 2. liver function 3. kidney function 4. Iron profile(serum iron ,serum ferritin 5. ESR (erythrocyte sedimentation rate ) g-CRP (C reactive protein) f-LDH (lactate dehydrogenase) 4. Abdominal us(the colon wall thickness,lymph nodes,mass,other organs) 5. Doppler us (mesenteric vessels) 6. colonoscopy after 1 year of treatment follow up every 3 months by abdominal US and peripheral hemogram and last visit after 1 year colonoscopy and biopsy for assessment response to treatment

Registry
clinicaltrials.gov
Start Date
July 1, 2018
End Date
October 1, 2021
Last Updated
2 years ago
Study Type
Observational
Sex
All

Investigators

Responsible Party
Principal Investigator
Principal Investigator

hyam fathy

clinical professor

Assiut University

Eligibility Criteria

Inclusion Criteria

  • Not provided

Exclusion Criteria

  • Not provided

Arms & Interventions

patient on traditional therapy

Drug: steroid,5ASA , immuran for assesment the outcome of therapy in inflammatory bowel disease steroid(40- 60mg tablet),5ASA(pentasa 3-4gm tablet),azathioprin (immuran 100 mg tablet)

Intervention: Infliximab

patient on infliximab

drug : infliximab (5mglkg intravenous)for the first dose,the second dose after 2 weeks the third dose after 6 weeks then every 2 months

Intervention: Infliximab

Outcomes

Primary Outcomes

the role abdominal ultrasound in assessment inflammatory bowel disease

Time Frame: 2 year

measure the thickness of the colon by abdominal ultrasound and doppler mesenteric vessels .more than 4ml detect activity doppler mesenteric highly vascularity in activity

Study Sites (1)

Loading locations...

Similar Trials